CLRB News and Press, Cellectar Biosciences Inc. From 02/23/22

Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the dis...

FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced Jim Caruso, presi...

Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma Mean ORR of 45.5%, CBR of 72.7% and DCR of 100% and the subset of quad/penta drug refractory patients had an ORR of 80% and CBR of 100% FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE ...

5 Penny Stocks To Watch With Potential Catalysts It’s the weekend, and we’re nearing the end of the year. But that doesn’t mean the stock market closes anytime soon. December is always an interesting time for traders. Some are looking to cut some heavy bags and harv...

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presenta...

FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in ...

Cellectar Biosciences (NASDAQ:CLRB): Q3 GAAP EPS of -$0.10 beats by $0.01. As of September 30, 2021, the company had cash and cash equivalents of $40.3M compared to $57.2M at December 31, 2020. Press Release For further details see: Cellectar Biosciences EPS beats by $0.01

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quar...

With the departure of John Friend as its chief medical officer, Cellectar Biosciences (NASDAQ:CLRB) has appointed former company consultant Laurence Reilly to the role in an interim capacity. Former CMO, Friend, is stepping down due to personal reasons, but he will serve the company thro...

FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced it is collaborating with BBK Worldwi...